Abstract

Much controversy surrounds the choice of optimal candidates for the prophylaxis of respiratory syncytial virus (RSV) based on published cost-effective measurements. The measurement of indirect costs associated with chronic illness is increasingly being recognized as a critical portion in understanding total health-care costs. The addition of indirect cost information to current cost-effectiveness ratios can potentially alter the approval coverage for treatment by payer groups.